Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2016-08-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
关于签订重组口蹄疫亚单位基因工程疫苗系列产品技术开发（合作）合同的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about signing a technology development cooperation contract related to recombinant foot-and-mouth disease subunit gene-engineered vaccine products. It details the background, cooperation parties, contract content, and potential impact on the company. There are no financial statements, no quarterly or annual financial data, no earnings highlights, no voting results, no management changes, no audit information, and no regulatory certifications. The document is an announcement of a business cooperation agreement, not a financial report or regulatory filing. It is also relatively short (3365 characters) and does not contain detailed financial or operational data. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2016-08-23 Chinese
关于对暂时闲置募集资金和自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the company's use of temporarily idle raised funds and own funds for cash management through purchasing financial products. It details the amounts, types, expected returns, risk control measures, and impact on company operations. The document is relatively short (3014 characters) and focuses on a specific financing activity related to cash management of idle funds, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion of results. It is not a report publication announcement since it contains substantive information about the cash management transactions. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage.
2016-08-22 Chinese
2016年半年报募集资金存放与实际使用情况的专项报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2016年半年报募集资金存放与实际使用情况的专项报告" which translates to a "Special Report on the Storage and Actual Use of Raised Funds for the 2016 Half-Year Report." It details the amount of funds raised, their usage, management, and investment projects related to the raised funds. The document includes detailed financial figures and tables about the use of funds during the first half of 2016. It is a comprehensive report on the use of capital raised by the company, specifically focusing on the half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. The document is over 6,000 characters and contains detailed financial data, so it is not a mere announcement or certification. Therefore, the correct classification is IR with high confidence. H1 2016
2016-08-18 Chinese
2016年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2016 年半年度报告摘要' which translates to '2016 Semi-Annual Report Summary'. It contains detailed financial data for the first half of 2016, including assets, net profit, revenue, and cash flow figures. It also includes management discussion and analysis (MD&A) of business performance, product development, marketing strategies, and future outlook. The document is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with an Interim / Quarterly Report as it covers a period shorter than a full fiscal year (half-year) and includes actual financial statements and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2016
2016-08-18 Chinese
2016年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2016 年半年度报告' which translates to '2016 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, accounting data, financial indicators, and operational performance for the period January 1, 2016 to June 30, 2016. The document is comprehensive, with over 15,000 characters, and includes financial statements and substantive financial data. It is not a brief announcement or a certification letter. The content matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year, containing actual financial statements and analysis. Therefore, the correct classification is IR with high confidence. H1 2016
2016-08-18 Chinese
信息披露暂缓与豁免业务内部管理制度
Governance Information Classification · 95% confidence The document is an internal management system for information disclosure delay and exemption by 普莱柯生物工程股份有限公司. It outlines procedures, conditions, and internal controls related to delaying or exempting disclosure of certain information, referencing regulatory rules such as the Securities Law and Shanghai Stock Exchange listing rules. The document is a policy or governance document rather than a financial report, earnings release, or announcement. It does not contain financial data, voting results, or legal proceedings. It is focused on governance practices related to information disclosure management. Therefore, the most appropriate classification is Governance Information (CGR). The document length is short (1820 characters), and it is not an announcement of a report but a substantive internal governance policy.
2016-08-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.